Abaxis (ABAX) Declares $0.12 Quarterly Dividend; 0.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2017 and Declares a Quarterly Cash Dividend
July 21, 2016 4:01 PM EDTUNION CITY, Calif., July 21, 2016 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the first fiscal quarter ended June 30, 2016.
First quarter overview:
Record revenues of $57.7 million, up 9% over last year's comparable quarter. Diluted net income per share of $0.30, down 3% from last year's comparable quarter, resulting from an increase of 2 percentage points in operating expenses as a percentage of revenues, due to initiatives to increase investments in research and... MoreAbaxis Reports Financial Performance for the First Quarter of Fiscal 2017 and Declares a Quarterly Cash Dividend
July 21, 2016 4:01 PM EDTUNION CITY, Calif., July 21, 2016 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the first fiscal quarter ended June 30, 2016.
First quarter overview:
Record revenues of $57.7 million, up 9% over last year's comparable quarter. Diluted net income per share of $0.30, down 3% from last year's comparable quarter, resulting from an increase of 2 percentage points in operating expenses as a percentage of revenues, due to initiatives to increase investments in research and... More